Novel arylglycinamide derivatives, method of producing said derivatives and pharmaceutical compositions containing these compounds

Abstract

The invention relates to new arylglycinamide derivatives of general formula I 1

Description

[0001] The invention relates to new arylglycinamide derivatives of general formula 3

[0002] and the pharmaceutically acceptable salts thereof, processes for preparing them and pharmaceutical compositions containing these compounds. The compounds are valuable neurokinin (tachykinin) antagonists.

[0003] The abbreviations used in this specification and claims are explained as follows:

CDI  Carbonyldiimidazole
DCCI Dicyclohexylcarbodiimide
HOBt 1-Hydroxybenzotriazole
THF  Tetrahydrofuran
DMF  Dimethylformamide
RT   Room temperature
DMAP 4-Dimethylaminopyridine
TBTU O-Benzotriazolyl-tetramethyluronium-
     tetrafluoroborate

[0004] The formulae are shown in simplified form. In representing the compounds, for example, all the CH3-substituents are represented by a hyphen and CH is represented by, thus, for example: 4

[0005] The invention relates to new arylglycinamide derivatives of general formula I 5

[0006] or the pharmaceutically acceptable salts thereof, wherein

[0007] Ar denotes unsubstituted or mono- to penta-substituted phenyl, or unsubstituted or mono- or disubstituted naphthyl [wherein the substituents of the phenyl and naphthyl independently of one another denote halogen (F, Cl, Br, I), (C1-4)alkyl, O—(C1-4)alkyl, CF3, OCF3 or NR12R13 (wherein R12 and R13 independently of one another denote H, methyl or acetyl)] or Ar is phenyl substituted by —O—CH2—O— or —O—(CH2)2—O—;

[0008] R1 and R2 together with the N to which they are bound denote a ring of the formula 6

[0009]  wherein

[0010] r, s and t are 2 or 3;

[0011] R6 denotes

[0012] H,

[0013] (C1-5)alkyl,

[0014] (C3-5)alkenyl,

[0015] propynyl,

[0016] hydroxy(C2-4)alkyl,

[0017] methoxy(C2-4)alkyl,

[0018] di(C1-3)alkylamino(C2-4)alkyl,

[0019] amino(C2-4)alkyl,

[0020] amino,

[0021] di(C1-3)alkylamino,

[0022] monofluoro- to perfluoro(C1-2)alkyl,

[0023] N-methylpiperidinyl,

[0024] pyridyl,

[0025] pyrimidinyl,

[0026] pyrazinyl,

[0027] pyridazinyl

[0028] or the group —CH2—C(O)NR14R15,

[0029]  wherein

[0030] R14 is H or (C1-4)alkyl and

[0031] R15 is H, (C1-4)alkyl, (C3-6)cycloalkyl, hydroxy(C2-4)alkyl, alkoxy(C2-3)alkyl, phenyl(C1-4)alkyl, or R14 and R15 together with the N to which they are bound form a ring (1-pyrrolidinyl, piperidino, morpholino or 1-methylpiperazin-4-yl);

[0032] R7 has one of the definitions (a) to (d),

[0033] (a) hydroxy

[0034] (b) 4-piperidinopiperidyl, 7

[0035]  wherein R16 and R17 independently of one another denote

[0036] H,

[0037] (C1-4)alkyl,

[0038] (C3-6)cycloalkyl,

[0039] hydroxy(C2-4)alkyl,

[0040] (C1-3)alkoxy(C2-4)alkyl,

[0041] phenyl(C1-4)alkyl or

[0042] di(C1-3)alkylamino(C2-4)alkyl,

[0043] or if R16 is H or (C1-4)alkyl,

[0044] R17 may also be —CH2C(O)NR18R19, wherein R18 and R19 are defined as R14 and R15 hereinbefore; 8

[0045]  wherein R20 denotes

[0046] H,

[0047] (C1-4)alkyl,

[0048] (C4-6)cycloalkyl or

[0049] —CH2C(O)NR21R22,

[0050] wherein R21 and R22 are defined as R14 and R15 hereinbefore;

[0051] R8 is H

[0052] R9 and R10 independently of each other denote (C1-4)alkyl;

[0053] R11 denotes

[0054] H,

[0055] (C1-5)alkyl,

[0056] (C3-5)alkenyl,

[0057] propynyl,

[0058] hydroxy(C2-4)alkyl,

[0059] methoxy(C2-3)alkyl,

[0060] di(C1-3)alkylamino(C2-3)alkyl,

[0061] amino(C2-3)alkyl,

[0062] amino,

[0063] di(C1-3)alkylamino,

[0064] monofluoro- to perfluoro(C1-2)alkyl,

[0065] N-methylpiperidinyl,

[0066] pyridyl,

[0067] pyrimidinyl,

[0068] pyrazinyl,

[0069] pyridazinyl

[0070] or the group —CH2—C(O)NR23R24,

[0071] wherein R23 and R24 are defined as R14 and R15 hereinbefore;

[0072] R3 denotes H, (C1-4)alkyl, unsubstituted or mono- to trisubstituted phenyl, wherein the substituents independently of one another denote halogen (F, Cl, Br, I), (C1-4)alkyl, O—(C1-4)alkyl, CF3, OCF3 or NR25R26 (wherein R25 and R26 independently of one another denote H, methyl or acetyl);

[0073] R4 denotes phenyl(C1-4)alkyl or naphthyl(C1-4)alkyl, wherein phenyl may be substituted by 1 to 3 substituents, wherein the substituents independently of one another denote halogen (F, Cl, Br, I), (C1-4)alkyl, O—(C1-4)alkyl, CF3, OCF3 or NR27R28 (wherein R27 and R28 independently of one another denote H, methyl or acetyl); and

[0074] R5 denotes H, (C1-4)alkyl, (C3-6)cycloalkyl, CH2COOH, CH2C(O)NH2, OH or phenyl(C1-4)alkyl.

[0075] Preferred compounds of general formula I are those wherein

[0076] Ar denotes unsubstituted or mono- or disubstituted phenyl, or unsubstituted naphthyl, or Ar is phenyl substituted by —O—CH2—O— or —O—(CH2)2—O—;

[0077] R1 and R2 together with the N to which they are bound denote a ring of the formula 9

[0078]  wherein

[0079] r is 2 or 3 and

[0080] s and t are 2;

[0081] R6, R7, R8, R9, R10 and R11 are as hereinbefore defined;

[0082] R3 is H or (C1-4)alkyl,

[0083] R4 denotes phenyl(C1-4)alkyl or naphthyl(C1-4)alkyl, wherein phenyl may be substituted by 1 or 2 substituents, wherein the substituents independently of one another are halogen (F, Cl, Br, I), (C1-4)alkyl, O—(C1-4)alkyl, CF3 or OCF3; and

[0084] R5 denotes H, (C1-4)alkyl, (C3-6)cycloalkyl, OH or (C1-4)alkylphenyl.

[0085] Particular mention should be made of compounds of formula I wherein

[0086] Ar is unsubstituted or mono- or disubstituted phenyl, or unsubstituted naphthyl [wherein the substituents of the phenyl independently of one another are halogen (F, Cl, Br, I), methyl, methoxy, CF3 or OCF3] or Ar is phenyl substituted by —O—CH2—O— or —O—(CH2)2—O—;

[0087] particularly those wherein Ar is phenyl, naphthyl, phenyl substituted in position 3 and/or 4 by methoxy or halogen, or phenyl in which positions 2 and 3 or 3 and 4 are linked by —O—CH2—O—, preferably those compounds wherein

[0088] Ar is phenyl, phenyl substituted by methoxy in positions 3 and 4 or phenyl wherein positions 3 and 4 or 2 and 3 are linked by —O—CH2—O—.

[0089] Of the compounds defined above, special mention should be made of those wherein, in the ring 10

[0090] r is 2 or 3 and

[0091] R6 denotes

[0092] H,

[0093] (C1-5)alkyl,

[0094] (C3-5)alkenyl,

[0095] propynyl,

[0096] hydroxy(C2-4)alkyl,

[0097] methoxy(C2-4)alkyl,

[0098] di(C1-3)alkylamino(C2-4)alkyl,

[0099] amino(C2-4)alkyl,

[0100] amino,

[0101] di(C1-3)alkylamino,

[0102] monofluoro- to perfluoro(C1-2)alkyl,

[0103] N-methylpiperidinyl,

[0104] pyridyl,

[0105] pyrimidinyl, or 11

[0106]  particularly those wherein

[0107] r is 3 and R6 is methyl;

[0108]  and those wherein

[0109] r is 2 and

[0110] R6 is

[0111] H,

[0112] (C1-4)alkyl,

[0113] propenyl,

[0114] propynyl,

[0115] hydroxy(C2-3)alkyl,

[0116] methoxyethyl,

[0117] di(C1-2)alkylamino(C2-3)alkyl,

[0118] aminoethyl,

[0119] amino,

[0120] dimethylamino,

[0121] CH2CF3,

[0122] N-methylpiperidinyl,

[0123] pyridyl,

[0124] pyrimidinyl, or 12

[0125]  preferably those wherein

[0126] r is 2 and

[0127] R6 is H, (C1-3)alkyl, allyl, 2-propynyl, —CH2CH2OCH3, —CH2CH2N(CH3)2, N-methylpiperidinyl, 2-pyrimidinyl or 13

[0128]  particularly those wherein

[0129] r is 2 and

[0130] R6 is H, CH3, C3H7, CH(CH3)2, CH2CH2OH, CH2CH2OCH3 or CH2C2N(CH3)2.

[0131] Of the compounds defined above, mention should also be made of those wherein

[0132] R1 and R2 together with the N to which they are bound form the ring 14

[0133]  wherein

[0134] R8 is H and

[0135] R7 is OH 15

[0136]  wherein R16 and R17 independently of one another denote:

[0137] H

[0138] (C1-3)alkyl, 16

[0139] (CH2)nOH wherein n is 2, 3 or 4 (CH2)2OCH3

[0140] —(CH2)nPh wherein n is 2 or 4 (CH2)2N(CH3)2 17

[0141]  particularly those wherein

[0142] R16 and R17 are both CH3 or C2H5 or

[0143] R16 is H or CH3 and R17 is

[0144] (C1-3)alkyl, 18

[0145] (CH2)2OH,

[0146] (CH2)4OH or 19

[0147]  and those wherein

[0148] R7 denotes 20

[0149] N(CH3)2 21

[0150]  or 22

[0151]  especially those wherein

[0152] R1 and R2 together with the N to which they are bound form the ring 23

[0153]  wherein

[0154]  (a)

[0155] R8 is H and

[0156] R7 is 24

[0157] wherein R16 and R17 both represent CH3, C2H5 l or CH2CH2OH or R16 is H or CH3 and R17 is (C1-3)alkyl, 25

[0158] (CH2)2OH or

[0159] (CH2)4OH or

[0160]  (b)

[0161] R8 is H and

[0162] R7 denotes 26

[0163] Of the compounds defined above, mention should also be made of those wherein

[0164] R1 and R2 together with the N to which they are bound form the ring 27

[0165] Of the compounds defined above, special mention should also be made of those wherein

[0166] R1 and R2 together with the N to which they are bound form the ring 28

[0167]  wherein R11 is H or (C1-3)alkyl, particularly those wherein

[0168] R11 is —CH(CH3)2.

[0169] Of the compounds defined above, the ones of particular interest are those wherein R3 is H; and/or

[0170] R4 denotes phenyl(C1-4)alkyl, wherein phenyl may be substituted by 1 or 2 substituents, wherein the substituents independently of one another denote halogen (F, Cl, Br, I), (C1-4)alkyl, O—(C1-4)alkyl, CF3 or OCF3; and/or

[0171] R5 denotes H, (C1-4)alkyl, (C3-6)cycloalkyl, —OH or phenyl(C1-4)alkyl,

[0172] particularly those wherein

[0173] R4 denotes phenyl(C2-4)alkyl, wherein the substituents are in positions 3 and/or 5 of the phenyl ring and/or

[0174] R5 is H, methyl, OH or phenethyl,

[0175] preferably those wherein 29

[0176] and R5 is methyl.

[0177] Compounds of general formula I may have acid groups, chiefly carboxyl groups, and/or basic groups such as amino functions, for example. Compounds of general formula I may therefore be present either as internal salts, as salts with pharmaceutically acceptable inorganic acids such as hydrochloric acid, sulphuric acid, phosphoric acid, sulphonic acid or organic acids (such as maleic acid, fumaric acid, citric acid, tartaric acid or acetic acid) or as salts with pharmaceutically acceptable bases such as alkali or alkaline earth metal hydroxides or carbonates, zinc or ammonium hydroxides or organic amines such as dimethylamine, triethylamine, triethanolamine, etc.

[0178] The compounds according to the invention may occur as racemates but may also be obtained as pure enantiomers, i.e. in the (R)- or (S)-form.

[0179] The term naphthyl used hereinbefore includes both 1-naphthyl and 2-naphthyl.

[0180] Test results for compounds according to the invention:

[0181] The receptor affinity for the NK1-receptor (substance P-receptor) is determined on human lymphoblastoma cells (IM-9) with cloned NK1-receptors, by measuring the displacement of 125I-labelled substance P. The K1-values thus obtained show the efficacy of the compounds:

           Ki [nM]
Example 1  1.2
Example 2  1.0
Example 3  19
Example 4  1.4
Example 5  1.5
Example 8  1.8
Example 9  2.5
Example 11 3.8
Example 12 5.0
Example 13 2.4
Example 15 0.98
Example 16 0.90
Example 17 7.75
Example 18 0.96
Example 19 1.17
Example 20 2.0
Example 22 2.2
Example 23 2.5
Example 24 2.2
Example 25 6.0
Example 26 1.6
Example 28 1.3
Example 30 1.8
Example 32 1.3
Example 33 7.4
Example 34 2.9
Example 47 1.7
Example 55 1.25
Example 63 1.4
Example 64 1.1
Example 65 5.7
Example 73 2.0
Example 74 1.5
Example 75 0.44
Example 76 2.0

[0182] The compounds according to the invention are valuable neurokinin (tachykinin) antagonists which have both substance P antagonism and also neurokinin A and neurokinin B antagonistic properties. They are useful for the treatment and prevention of neurokinin-mediated diseases:

[0183] for the treatment or prevention of inflammatory and allergic diseases of the respiratory tract, such as asthma, chronic bronchitis, hyperreactive respiratory tract, emphysema, rhinitis and cough,

[0184] and of the eyes, such as conjunctivitis and iritis,

[0185] of the skin, such as dermatitis in contact eczema, urticaria, psoriasis, sunburn, insect bites and stings, itching, sensitive or hypersensitive skin,

[0186] of the gastrointestinal tract, such as gastric and duodenal ulcers, ulcerative colitis, Crohn's disease, irritable bowel and Hirschsprung's disease,

[0187] of the joints, such as rheumatoid arthritis, reactive arthritis and Reiter syndrome;

[0188] for treating diseases of the central nervous system such as dementia, Alzheimer's disease, schizophrenia, psychoses, depression, headache (e.g. migraine or tension headaches), epilepsy, Parkinson's disease and stroke;

[0189] for treating herpes zoster and postherpetic pain, tumours, collagenoses, dysfunction of the deferent urinary tract, haemorrhoids, nausea and vomiting, caused for example by radiation or cytostatic therapy or motion and pain of all kinds.

[0190] The invention therefore also relates to the use of the compounds according to the invention as therapeutic agents and pharmaceutical preparations which contain these compounds. They are preferably used in humans. The compounds according to the invention may be administered by intravenous, subcutaneous, intramuscular, intraperitoneal or intranasal route, by inhalation, by transdermal route, optionally aided by iontophoresis or enhancers known from the literature, and by oral route.

[0191] For parenteral administration the compounds of formula I or the physiologically acceptable salts thereof, possibly with the conventional substances such as solubilisers, emulsifiers or other adjuvants, are dissolved, suspended or emulsified. Solvents which may be used include: water, physiological saline solutions or alcohols, e.g. ethanol, propanediol or glycerol, sugar solutions such as glucose or mannitol solutions or a mixture of several solvents.

[0192] In addition, the compounds may be administered by means of implants, e.g. of polylactide, polyglycolide or polyhydroxybutyric acid or intranasal preparations.

[0193] The oral efficacy of compounds of general formula I can be demonstrated by the following standard test:

[0194] Inhibition of lowering of blood pressure caused by NK1 in anaesthetised guinea pigs.

[0195] Guinea pigs weighing 300-500 grams were anaesthetised with pentobarbital (50 mg/kg i.p.), intubated and artificially ventilated. They were ventilated with 10 ml/kg of air at a frequency of 60 breaths per minute. The carotid artery was canulated and the arterial blood pressure was recorded. A polyethylene tube was inserted-into the jugular vein for the intravenous supply of substances.

[0196] A temporary reduction in blood pressure was brought about at intervals of 10 minutes by intravenous administration of the NK1-agonist [βAla4, Sar9, Met (O2)11]Sp(4-11) 30

[0197] in a dose of 0.2 μmol/kg. After the blood pressure thus produced had been measured, the test compound was introduced into the duodenum and the NK1-agonist was again injected every 10 minutes.

[0198] The results were expressed as a % inhibition of the reduction in blood pressure caused by the NK1-agonist specified.

[0199] In a dosage of 1 mg/kg (administered into the duodenum) the compound of Example 1 inhibited the lowering of blood pressure caused by the NK1-agonist by 80%.

[0200] The compounds according to the invention can be produced using generally known methods.

[0201] The compounds may be prepared in various ways. The two most common procedures are represented by the following diagram: 31

[0202] Method A. The carboxylic acid may be linked to the amine HN(R5)R4 by various methods. Conventional methods are coupling processes such as those used in peptide chemistry. A coupling reagent such as TBTU, DCCI/HOBt, CDI, etc., is added to the coupling partners in substantially equivalent quantities. Suitable solvents are DMF, THF, CH2Cl2, CHCl3, acetonitrile or other inert solvents or mixtures thereof. The suitable temperature range is between −50° C. and +120° C., preferably between 0° C. and 40° C.

[0203] The carboxylic acid may also initially be converted into the corresponding acid halide by known methods using SOCl2, SO2Cl2, PCl3, PCl5 or PBr3 or mixtures thereof, and the acid halide is then reacted with the amine HN(R5)R4 in an inert solvent such as CH2Cl2, THF or dioxane at temperatures between −50° C. and +100° C., typically at 0° to 20° C.

[0204] Another alternative is to convert the carboxylic acid initially into the alkylester, usually the methylester, by known methods and this ester is then reacted with the amine HN(R5)R4 in an inert solvent such as DMF, dioxane or THF. The reaction temperatures are between 20° C. and 150° C., typically between 50° C. and 120° C. The reaction may also be carried out in a pressurized container.

[0205] Method B. Here, the α-halo-arylacetamide derivative obtained by known methods is reacted with the amine R1(R2)NH, thereby cleaving hydrogen halide. Inorganic bases such as K2CO3, NaHCO3 or CaCO3 or organic bases such as triethylamine, Hünig base, pyridine or DMAP are used to mop up the cleaved (or excess) hydrogen halide, or an excess of the amine R1(R2)NH may be used. DMF, THF, dioxane or other inert solvents are used. The temperature range for the reaction is from 0 to 100° C., typically between 10 and 80° C.

[0206] Method C. The compounds according to the invention wherein R5 is not H may also be prepared as follows: first of all, the corresponding compound in which R5 is H is synthesised using method A or B. Then, N-alkylation is carried out as follows in order to introduce alkyl, cycloalkyl or CH2COOH. The compounds according to the invention wherein R5 is H are deprotonated with an equivalent quantity of NaH, NaNH2, KOH, NaOCH3 or another strong base. Anhydrous inert solvents such as THF, dioxane or diethylether are used for this. Then the corresponding alkylating agent is added slowly in the form of the corresponding halide, tosylate or mesylate. The reaction is carried out at a temperature within the range from −50° C. to +100° C., typically between 0° C. and +50° C.

EXAMPLE 1

[0207] 32

[0208] Mp.: 105-115° C.

[0209] FAD-MS: (M+H)+=516.3.

[0210] 1st step: 0.71 q of 1-isopropylpiperazine were dissolved in 55 ml of anhydrous DMF, mixed with 0.64 g of Na2CO3, stirred for 20 minutes at RT and then cooled to 5° C. 1.15 g of methyl (R,S)-α-bromophenylacetate were added and the suspension was stirred overnight at RT. The precipitate was filtered off and the filtrate was evaporated down. The residue was taken up in ethyl acetate, extracted twice with 10% KHCO3 solution and once with saturated NaCl solution. The organic phase was dried over Na2SO4, filtered and evaporated down, to yield 1.23 g of methyl (R,S)-1-isopropyl-4-(2-phenylacetate)piperazine as a viscous oil. Yield: about 89%.

[0211] 2nd step: 1.23 g of the product from the 1st step were dissolved in 10 ml of methanol and 10 ml of THF, mixed with 10 ml of 1N NaCH and the mixture was stirred overnight at ambient temperature. The clear reaction solution was neutralised by the addition of 10 ml of 1N HCl, evaporated to dryness, the residue was treated with DMF and the solid was separated by suction filtering. The filtrate was evaporated down and the residue was triturated with ether, the solid substance removed by suction filtering and dried in a desiccator. In this way, 1.1 g of (R,S)-1-i-propyl-4-(2-phenylacetic acid)piperazine were obtained as a solid white substance. Yield: 92%.

[0212] 3rd step: 0.37 g of the product of the 2nd step and 0.42 g of N-methyl-3,5-bis-(trifluoromethyl)phenylethylamine were dissolved in 14 ml of DMF and adjusted to pH 8.5 by the addition of about 0.4 ml of TEA. 0.48 g of TBTU were added and the mixture was stirred overnight at room temperature. The clear reaction solution was evaporated down in vacuo, the residue was stirred with NaHCO3 solution and extracted twice with ethyl acetate. The combined organic phases were filtered and the filtrate was evaporated down. The residue was chromatographed over silica gel using CH2Cl2/MeOH (9:1) as eluant. The uniform fractions obtained were evaporated down, dissolved in a little MeOH, acidified with ethereal HCl and evaporated down again. The residue was triturated with ether and dried in a desiccator. 0.58 g of (R,S)-1-i-propyl-4-[2-phenylacetic acid-N-methyl-N-(3,5-bistrifluoromethylphenylethyl)]-amide dihydrochloride were obtained as a solid white substance. Yield: 75%.

[0213] The other compounds of the invention may be prepared analogously, e.g. the following:

EXAMPLE 2

[0214] 33

EXAMPLE 3

[0215] 34

EXAMPLE 4

[0216] 35

EXAMPLE 5

[0217] 36

EXAMPLE 6

[0218] 37

EXAMPLE 7

[0219] 38

EXAMPLE 8

[0220] 39

EXAMPLE 9

[0221] 40

EXAMPLE 11

[0222] 41

EXAMPLE 12

[0223] 42

EXAMPLE 13

[0224] 43

EXAMPLE 15

[0225] 44

EXAMPLE 16

[0226] 45

EXAMPLE 17

[0227] 46

EXAMPLE 18

[0228] 47

EXAMPLE 19

[0229] 48

EXAMPLE 20

[0230] 49

EXAMPLE 22

[0231] 50

EXAMPLE 23

[0232] 51

EXAMPLE 24

[0233] 52

EXAMPLE 25

[0234] 53

EXAMPLE 26

[0235] 54

EXAMPLE 27

[0236] 55

EXAMPLE 28

[0237] 56

EXAMPLE 29

[0238] 57

EXAMPLE 30

[0239] 58

EXAMPLE 31

[0240] 59

EXAMPLE 32

[0241] 60

EXAMPLE 33

[0242] 61

EXAMPLE 34

[0243] 62

EXAMPLE 35

[0244] 63

EXAMPLE 36

[0245] 64

EXAMPLE 37

[0246] 65

EXAMPLE 38

[0247] 66

EXAMPLE 39

[0248] 67

EXAMPLE 40

[0249] 68

EXAMPLE 41

[0250] 69

EXAMPLE 42

[0251] 70

EXAMPLE 43

[0252] 71

EXAMPLE 44

[0253] 72

EXAMPLE 45

[0254] 73

EXAMPLE 46

[0255] 74

EXAMPLE 47

[0256] 75

EXAMPLE 48

[0257] 76

EXAMPLE 49

[0258] 77

EXAMPLE 50

[0259] 78

EXAMPLE 51

[0260] 79

EXAMPLE 53

[0261] 80

EXAMPLE 54

[0262] 81

EXAMPLE 55

[0263] 82

EXAMPLE 56

[0264] 83

EXAMPLE 57

[0265] 84

EXAMPLE 58

[0266] 85

EXAMPLE 59

[0267] 86

EXAMPLE 60

[0268] 87

EXAMPLE 61

[0269] 88

EXAMPLE 63

[0270] 89

EXAMPLE 64

[0271] 90

EXAMPLE 65

[0272] 91

EXAMPLE 66

[0273] 92

EXAMPLE 67

[0274] 93

EXAMPLE 68

[0275] 94

EXAMPLE 69

[0276] 95

EXAMPLE 70

[0277] 96

EXAMPLE 71

[0278] 97

EXAMPLE 72

[0279] 98

EXAMPLE 73

[0280] 99

EXAMPLE 74

[0281] 100

EXAMPLE 75

[0282] 101

EXAMPLE 76

[0283] 102

[0284] Of these compounds, the compounds of Examples 1 and 8 are preferred.

[0285] In the foregoing representations of the formulae, the CH3 groups are not drawn in full.

[0286] Compound 1, for example, contains a methyl group as the group R5.

Pharmaceutical preparations
Injectable solution
200	mg	of active substance*
1.2	mg	of monopotassium dihydrogen
		phosphate = KH2PO4
0.2	mg	of disodium hydrogen phosphate =	{close oversize brace}	(buffer)
		Na2HPO4.2H2O
94	mg	sodium chloride
or			{close oversize brace}	(isotonic agents)
520	mg	glucose
4	mg	albumin		(protease protection)
q.s.		sodium hydroxide solution
			{close oversize brace}	ad pH 6
q.s.		hydrochloric acid
ad 10	ml	water for injections
Injectable solution
200	mg	active substance*
94	mg	sodium chloride
or
520	mg	glucose
4	mg	albumin
q.s.		sodium hydroxide solution
			{close oversize brace}	ad pH 9
q.s.		hydrochloric acid
ad 10	ml	water for injections
Lyophilisate
200	mg	of active substance*
520	mg	of mannitol (isotonic agent/framework
		agent)
4	mg	albumin
Solvent 1	for lyophilisate
10	ml	of water for injections
Solvent 2	for lyophilisate
20	mg	of Polysorbate ®80 = Tween ®80
		(surfactant)
10	ml	of water for injections
*Active substance: compound according to the invention, e.g. one of Examples 1 to 76
Dosage for humans weighing 67 kg: 1 to 500 mg

Claims

1. Arylglycinamide derivatives of general formula I

2. Compound according to claim 1 wherein Ar denotes unsubstituted or mono- or disubstituted phenyl, or unsubstituted naphthyl, or Ar is phenyl substituted by —O—CH2—O— or —O—(CH2)2—O—; R1 and R2 together with the N to which they are bound denote a ring of the formula 107 wherein r is 2 or 3 and s and t are 2; R6, R7, R8, R9, R10 and R11 are defined as in claim 1;R3 is H or (C1-4)alkyl, R4 denotes phenyl(C1-4)alkyl or naphthyl(C1-4)alkyl, wherein phenyl may be substituted by 1 or 2 substituents, wherein the substituents independently of one another are halogen (F, Cl, Br, I), (C1-4)alkyl, O—(C1-4)alkyl, CF3 or OCF3; and R5 denotes H, (C1-4)alkyl, (C3-6)cycloalkyl, OH or phenyl(C1-4)alkyl.

3. Compound according to claim 1 or 2, wherein Ar is unsubstituted or mono- or disubstituted phenyl, or unsubstituted naphthyl [wherein the substituents of the phenyl independently on one another denote halogen (F, Cl, Br, I), methyl, methoxy, CF3 or OCF3] or Ar is phenyl substituted by —O—CH2—O— or —O—(CH2)2—O—.

4. Compound according to claim 3, wherein Ar is phenyl, naphthyl, phenyl substituted by methoxy or halogen in position 3 and/or 4 or phenyl wherein positions 2 and 3 or 3 and 4 are linked by —O—CH2—O—.

5. Compound according to claim 4, wherein Ar is phenyl, phenyl substituted by methoxy in positions 3 and 4 or phenyl in which positions 3 and 4 or 2 and 3 are linked by —O—CH2—O—.

6. Compound according to one of claims 1 to 5, wherein in the ring

7. Compound according to claim 6, wherein r is 3 and R6 is methyl.

8. Compound according to claim 6, wherein r is 2 and R6 is H, (C1-4)alkyl, propenyl, propynyl, hydroxy(C2-3)alkyl, methoxyethyl, di(C1-2)alkylamino(C2-3)alkyl, aminoethyl, amino, dimethylamino, CH2CF3, N-methylpiperidinyl, pyridyl, pyrimidinyl or 110

9. Compound according to claim 8, wherein r is 2 and R6 is H, (C1-3)alkyl, allyl, 2-propynyl, —CH2CH2OCH3, —CH2CH2N(CH3)2, N-methylpiperidinyl, 2-pyrimidinyl or 111

10. Compound according to claim 9, wherein r is 2 and R6 is H, CH3, C3H7, CH(CH3)2, CH2CH2OH, CH2CH2OCH3 or CH2CH2N(CH3)2.

11. Compound according to one of claims 1 to 5, wherein R1 and R2 together with the N to which they are bound form the ring 112 wherein R8 is H and R7 is OH 113 wherein R16 and R17 independently of one another denote: H (C1-3)alkyl, 114(CH2)nOH wherein n is 2, 3 or 4 (CH2)2OCH3 —(CH2)nPh wherein n is 2 or 4 (CH2)2N(CH3)2 115

12. Compound according to claim 11, wherein R16 and R17 are both CH3 or C2H5 or R16 is H or CH3 and R17 is (C1-3)alkyl, 116

13. Compound according to claim 11 wherein R7 denotes 117

14. Compound according to claim 11, wherein R1 and R2 together with the N to which they are bound form the ring 118 wherein (a) R8 is H and R7 is 119 wherein R16 and R17 both represent CH3, C2H5 or CH2CH2OH or R16 is H or CH3 and R17 is (C1-3)alkyl, 120(CH2)2OH or (CH2)4OH or (b) R8 is H and R7 denotes 121

15. Compound according to one of claims 1 to 5, wherein R1 and R2 together with the N to which they are bound form the ring

16. Compound according to one of claims 1 to 5, wherein R1 and R2 together with the N to which they are bound form the ring

17. Compound according to claim 16, wherein R11 is —CH(CH3)2.

18. Compound according to one of claims 1 to 17, wherein R3 is H.

19. Compound according to one of claims 1 to 18, wherein R4 denotes phenyl(C1-4)alkyl, wherein phenyl may be substituted by 1 or 2 substituents, in which the substituents independently of one another are halogen (F, Cl, Br, I), (C1-4)alkyl, O—(C1-4)alkyl, CF3 or OCF3; and R5 denotes H, (C1-4)alkyl, (C3-6)cycloalkyl, —OH or phenyl(C1-4)alkyl.

20. Compound according to claim 19, wherein R4 denotes phenyl(C2-4)alkyl, wherein the substituents are in positions 3 and/or 5 of the phenyl ring and R5 is H, methyl, OH or phenethyl.

21. Compound according to claim 20, wherein R4 is

22. Process for preparing a compound of general formula I according to one of claims 1 to 21, characterised in that a) an acid 125 or a halide or alkylester thereof is reacted with an amine 126b) an α-haloarylacetamide 127 is reacted with an amine 128c) a compound I wherein R5 is H is N-alkylated; and a compound thus obtained is isolated as a free compound or as a pharmaceutically acceptable salt thereof.

23. Pharmaceutical preparation containing a compound according to one of claims 1 to 21 and pharmaceutically acceptable carriers and excipients.

24. Use of a compound according to one of claims 1 to 22 for preparing a pharmaceutical preparation for the treatment and prevention of neurokinin-mediated diseases.

25. Use of a compound according to one of claims 1 to 22 for the treatment and prevention of neurokinin-mediated diseases.